Patents by Inventor Amalio Telenti
Amalio Telenti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240059757Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. In certain embodiments, the presently disclosed antibodies are capable of binding to S proteins of multiple sarbecoviruses and/or neutralizing infection by multiple sarbecoviruses. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a sarbecovirus infection, such as a SARS-CoV-2 infection.Type: ApplicationFiled: April 14, 2021Publication date: February 22, 2024Inventors: Martina BELTRAMELLO, Siro BIANCHI, Elisabetta CAMERONI, Davide CORTI, Nadine CZUDNOCHOWSKI, Katja FINK, Florian A. LEMPP, Dora PINTO, Matteo Samuele PIZZUTO, Gyorgy SNELL, Amalio TELENTI, Fabrizia ZATTA
-
Publication number: 20230331821Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: ApplicationFiled: September 14, 2022Publication date: October 19, 2023Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
-
Publication number: 20230282305Abstract: Universal signatures represent generalizable features that are informative for generating predictions for different disease activities across different diseases. More specifically, one or more universal signatures are learned from data pertaining to a first disease indication and then applied to generate predictions for a one or more additional disease indications. The implementation of one or more universal signatures is useful for generating predictions for disease indications, such as disease indications involving rare or novel diseases, where it may be infeasible to develop a model due to insufficient training data.Type: ApplicationFiled: August 6, 2021Publication date: September 7, 2023Inventors: Amalio Telenti, Julia Di Iulio
-
Publication number: 20230210879Abstract: The present disclosure relates to methods of inhibiting replication of a respiratory virus, and methods of treating or preventing a respiratory virus infection in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a N-glycosylation pathway inhibitor.Type: ApplicationFiled: December 16, 2022Publication date: July 6, 2023Inventors: Dale R. Balce, Istvan Bartha, Johannes Grosse, Seungmin Hwang, Zachary Newby, Arnold Park, Leah B. Soriaga, Amalio Telenti, Winston C. Tse
-
Patent number: 11479599Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: GrantFiled: July 23, 2021Date of Patent: October 25, 2022Assignee: Vir Biotechnology, Inc.Inventors: Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
-
Publication number: 20210371504Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: ApplicationFiled: July 23, 2021Publication date: December 2, 2021Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
-
Patent number: 11168128Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: GrantFiled: February 25, 2021Date of Patent: November 9, 2021Assignee: VIR BIOTECHNOLOGY, INC.Inventors: Davide Corti, Katja Fink, Martina Beltramello, Elisabetta Cameroni, Dora Pinto, Gyorgy Snell, Florian A. Lempp, Amalio Telenti
-
Publication number: 20210261650Abstract: The instant disclosure provides antibodies and antigen-binding fragments thereof that can bind to a SARS-CoV-2 antigen and, in certain embodiments, are capable of neutralizing a SARS-CoV-2 infection. Also provided are polynucleotides that encode an antibody or antigen-binding fragment, vectors and host cells that comprise a polynucleotide, pharmaceutical compositions, and methods of using the presently disclosed antibodies, antigen-binding fragments, polynucleotides, vectors, host cells, and compositions to treat or diagnose a SARS-CoV-2 infection.Type: ApplicationFiled: February 25, 2021Publication date: August 26, 2021Inventors: Davide CORTI, Katja FINK, Martina BELTRAMELLO, Elisabetta CAMERONI, Dora PINTO, Gyorgy SNELL, Florian A. LEMPP, Amalio TELENTI
-
Publication number: 20200176077Abstract: Disclosed herein are methods and systems for determining regions, domains, or amino acid residues of proteins that are intolerant to mutation. Also disclosed are applications for visualizing intolerant proteins regions, domains, and amino acid residues.Type: ApplicationFiled: August 9, 2018Publication date: June 4, 2020Inventors: Amalio TELENTI, Michael HICKS, Istvan BARTHA
-
Publication number: 20190310269Abstract: The disclosure relates to systems, software and methods for diagnosis or prognosis of subjects for obesity or a disease related thereto, including, classification and treatment of subjects who have been diagnosed with or deemed at risk of having obesity. The methods are based, in part, on the detection of the levels or activities of a plurality of metabolites or their derivatives, such as levels of amino acids, carbohydrates, lipids, nucleic acids, and/or cofactors, in the subject's biological sample, e.g., blood.Type: ApplicationFiled: April 4, 2019Publication date: October 10, 2019Inventors: Elizabeth CIRULLI, Amalio TELENTI
-
Publication number: 20190209626Abstract: A probiotic composition comprises an effective amount of a combination of bacteria, wherein the combination of bacteria comprises certain at least one bacterium A selected from the Bacteroidetes phylum and certain at least one bacterium B selected from the Firmicutes phylum.Type: ApplicationFiled: January 7, 2019Publication date: July 11, 2019Inventors: Weizhong Li, Ericka L. Anderson, Lei Huang, William Biggs, Amalio Telenti, J. Craig Venter, Karen E. Nelson
-
Publication number: 20170329893Abstract: Described are genomic health risk metrics elaborated herein to hold significant advantages for the health care industry. The likelihood that any given GSV will be deleterious is relatively small. Since every human genome sequenced may result in several million GSVs, the advantage of a genomic health risk metric such as a tolerability score, an n-mer score, a context dependent tolerance score, or a protein tolerability score to clinicians is that it will allow them to focus on and prioritize deleterious mutations.Type: ApplicationFiled: May 8, 2017Publication date: November 16, 2017Inventors: Julia di Iulio, Amalio Telenti
-
Publication number: 20170270212Abstract: Disclosed are systems, media, and methods for providing a genomic search engine application comprising: a plurality of indices, recorded in the computer storage, the indices comprising tokenized genomic data; a software module providing an indexing pipeline, the indexing pipeline ingesting genomic data and annotation associated with the genomic data, tokenizing the data while preserving gene names and gene variant names, and updating the indices with the tokenized data; and a software module presenting a user interface allowing a user to enter a user query; a software module providing a query engine, the query engine accepting the user query, selecting one or more relevant indices, and applying a ranking formula to the selected indices to return ranked results.Type: ApplicationFiled: March 21, 2017Publication date: September 21, 2017Inventors: Victor Lavrenko, Amalio Telenti, Franz Josef Och
-
Patent number: 9536047Abstract: In this invention, we propose privacy-enhancing technologies for medical tests and personalized medicine methods, which utilize patients' genomic data. Assuming the whole genome sequencing is done by a certified institution, we propose to store patients' genomic data encrypted by a patient's public keys at a Storage and Processing Unit (SPU). A part of the corresponding private key is also stored on the SPU. At the time of the test by a Medical Unit (MU), the patient provides the second part of the private key to the MU. A test with its associated markers is determined by the MU and sent to the SPU. The test is carried out on the encrypted values thanks to homomorphic operation and returned back to the MU. The latter uses the second part of the private key to access the result.Type: GrantFiled: January 12, 2016Date of Patent: January 3, 2017Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)Inventors: Erman Ayday, Jean-Pierre Hubaux, Jean L. Raisaro, Amalio Telenti, Jacques Fellay, Paul J. McLaren, Jacques Rougemont, Mathias Humbert
-
Patent number: 9524370Abstract: A privacy-preserving method for performing a disease susceptibility test on a patient, said method comprising: (I) performing homomorphic computations, (J) obtaining a test result which is partly decrypted with a first part (prk1 resp. prk2) of a private key, (L) decrypting said partly decrypted result with a second part (prk2 resp. prk1) of said private key, wherein said homomorphic computations are based on encrypted genomic markers of the patient, on encrypted clinical and/or environmental markers, and on encrypted ancestry markers of the patient. The invention is also related to a method for inferring ancestry in the encrypted domain.Type: GrantFiled: November 3, 2014Date of Patent: December 20, 2016Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)Inventors: Jean L. Raisaro, Erman Ayday, Paul McLaren, Jean-Pierre Hubaux, Amalio Telenti
-
Publication number: 20160224735Abstract: In this invention, we propose privacy-enhancing technologies for medical tests and personalized medicine methods, which utilize patients' genomic data. Assuming the whole genome sequencing is done by a certified institution, we propose to store patients' genomic data encrypted by a patient's public keys at a Storage and Processing Unit (SPU). A part of the corresponding private key is also stored on the SPU. At the time of the test by a Medical Unit (MU), the patient provides the second part of the private key to the MU. A test with its associated markers is determined by the MU and sent to the SPU. The test is carried out on the encrypted values thanks to homomorphic operation and returned back to the MU. The latter uses the second part of the private key to access the result.Type: ApplicationFiled: January 12, 2016Publication date: August 4, 2016Inventors: Erman Ayday, Jean Pierre Hubaux, Jean Louis Raisaro, Amalio Telenti, Jacques Fellay, Paul Jack MCLAREN, Jacques Rougemont, Mathias Humbert
-
Publication number: 20160125141Abstract: A privacy-preserving method for performing a disease susceptibility test on a patient, said method comprising: (I) performing homomorphic computations, (J) obtaining a test result which is partly decrypted with a first part (prk1 resp. prk2) of a private key, (L) decrypting said partly decrypted result with a second part (prk2 resp. prk1) of said private key, wherein said homomorphic computations are based on encrypted genomic markers of the patient, on encrypted clinical and/or environmental markers, and on encrypted ancestry markers of the patient. The invention is also related to a method for inferring ancestry in the encrypted domain.Type: ApplicationFiled: November 3, 2014Publication date: May 5, 2016Inventors: Jean L. RAISARO, Erman AYDAY, Paul MCLAREN, Jean-Pierre HUBAUX, Amalio TELENTI
-
Patent number: 9270446Abstract: In this invention, we propose privacy-enhancing technologies for medical tests and personalized medicine methods, which utilize patients' genomic data. Assuming the whole genome sequencing is done by a certified institution, we propose to store patients' genomic data encrypted by a patient's public keys at a Storage and Processing Unit (SPU). A part of the corresponding private key is also stored on the SPU. At the time of the test by a Medical Unit (MU), the patient provides the second part of the private key to the MU. A test with its associated markers is determined by the MU and sent to the SPU. The test is carried out on the encrypted values thanks to homomorphic operation and returned back to the MU. The latter uses the second part of the private key to access the result.Type: GrantFiled: September 10, 2013Date of Patent: February 23, 2016Assignee: Ecole Polytechnique Federale de Lausanne (EPFL)Inventors: Erman Ayday, Jean-Pierre Hubaux, Jean Louis Raisaro, Amalio Telenti, Jacques Fellay, Paul Jack McLaren, Jacques Rougemont, Mathias Humbert
-
Publication number: 20150236849Abstract: In this invention, we propose privacy-enhancing technologies for medical tests and personalized medicine methods, which utilize patients' genomic data. Assuming the whole genome sequencing is done by a certified institution, we propose to store patients' genomic data encrypted by a patient's public keys at a Storage and Processing Unit (SPU). A part of the corresponding private key is also stored on the SPU. At the time of the test by a Medical Unit (MU), the patient provides the second part of the private key to the MU. A test with its associated markers is determined by the MU and sent to the SPU. The test is carried out on the encrypted values thanks to homomorphic operation and returned back to the MU. The latter uses the second part of the private key to access the result.Type: ApplicationFiled: September 10, 2013Publication date: August 20, 2015Applicant: Ecole Polytechnique Federale de Lausanne (EPFL)Inventors: Erman Ayday, Jean-Pierre Hubaux, Jean Louis Raisaro, Amalio Telenti, Jacques Fellay, Paul Jack Mc Laren, Jacques Rougemont, Mathias Humbert
-
Patent number: 6124098Abstract: A nucleotide sequence encoding a katG/lacZ fusion protein is useful for assaying the enzymatic activity of the katG gene product. A process of selecting a compound that is toxic against an isoniazid-resistant mycobaterial strain comprises incubating a catalase peroxidase enzyme with an isoniazid to produce a compound that restores isoniazid susceptability to the isoniazid-resistant mycobaterial strain.Type: GrantFiled: May 20, 1998Date of Patent: September 26, 2000Assignees: Institut Pasteur, Medical Research Council, Assistance Publique, Universite Pierre et Marie Curie (Paris VI), Universite de BerneInventors: Beate Heym, Stewart Cole, Douglas Young, Ying Zhang, Nadine Honore, Amalio Telenti, Thomas Bodmer